Q. Which of the following is not true regarding the immune checkpoint inhibitor durvalumab?
A. It leads to improvement in PFS when used in adjuvant setting after concurrent chemoradiation in stage III NSCLC patients.
B. It leads to significant increase in toxicity as compared with placebo
C. The improvement in survival endpoints is seen regardless of PD-L 1 status
D. In patients with EGFR mutation is likely to be ineffective
Answer: It leads to significant increase in toxicity as compared with placebo
